WATERTOWN, Mass.--(BUSINESS WIRE)--Panacos Pharmaceuticals, Inc. (NASDAQ:PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, today announced that its lead product candidate, the HIV maturation inhibitor bevirimat (PA-457), was the subject of two presentations at the 15th Conference on Retroviruses and Opportunistic Infections (CROI) held this week in Boston, MA.
